Who are Magnesium sulfate 24 hours's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): S-Ketamine 0.25, Ketamine (2st phase), Saline + Ketamine, Ketamine + methadone, Ketamine (1st phase), S-Ketamine 0.75.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/magnesium-sulfate-24-hours.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Magnesium sulfate 24 hours — Competitive Intelligence Brief

Magnesium sulfate 24 hours (Magnesium sulfate 24 hours) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist; tocolytic agent; anticonvulsant. Area: Obstetrics; Neurology; Cardiovascular.

marketed NMDA receptor antagonist; tocolytic agent; anticonvulsant NMDA receptor; L-type calcium channels Obstetrics; Neurology; Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Magnesium sulfate 24 hours (Magnesium sulfate 24 hours) — Instituto Materno Infantil Prof. Fernando Figueira. Magnesium sulfate acts as a central nervous system depressant and smooth muscle relaxant by blocking neuromuscular transmission and reducing acetylcholine release at the neuromuscular junction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Magnesium sulfate 24 hours TARGET	Magnesium sulfate 24 hours	Instituto Materno Infantil Prof. Fernando Figueira	marketed	NMDA receptor antagonist; tocolytic agent; anticonvulsant	NMDA receptor; L-type calcium channels
S-Ketamine 0.25	S-Ketamine 0.25	Turku University Hospital	marketed	NMDA receptor antagonist	NMDA receptor
Ketamine (2st phase)	Ketamine (2st phase)	Shalvata Mental Health Center	marketed	NMDA receptor antagonist	NMDA receptor
Saline + Ketamine	Saline + Ketamine	Ullevaal University Hospital	marketed	NMDA receptor antagonist / Dissociative anesthetic	NMDA receptor (glutamate-gated ion channel)
Ketamine + methadone	Ketamine + methadone	Cedars-Sinai Medical Center	marketed	NMDA receptor antagonist + synthetic opioid agonist combination	NMDA receptor (ketamine); mu opioid receptor (methadone)
Ketamine (1st phase)	Ketamine (1st phase)	Shalvata Mental Health Center	marketed	NMDA receptor antagonist	NMDA receptor
S-Ketamine 0.75	S-Ketamine 0.75	Turku University Hospital	marketed	NMDA receptor antagonist	NMDA receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist; tocolytic agent; anticonvulsant class)

Instituto Materno Infantil Prof. Fernando Figueira · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Magnesium sulfate 24 hours — Competitive Intelligence Brief. https://druglandscape.com/ci/magnesium-sulfate-24-hours. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab